Expanding the Reach of Menin Inhibitors

Megakaryocytes contribute substantially to the pathogenesis of myeloproliferative neoplasms (MPNs), but therapeutic strategies targeting this lineage are lacking. Wen, Cotton et al. demonstrate that menin inhibition impairs megakaryocyte differentiation, suppresses myelofibrosis and improves disease features across preclinical MPN models.